(Q24239909)

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Regression of existing glomerulosclerosis by inhibition of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Role of aldosterone in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Aldosterone in chronic kidney and cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Antihypertensive agents for primary prevention of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Aldosterone antagonists for preventing the progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Retarding the progression of renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007004.PUB2

7 January 2021